WillingMed Completes Series B Financing of CNY Hundreds of Millions to Accelerate the Layout of mNGS

Recently, WillingMed Technology(Beijing) Co., Ltd. announced the completion of a CNY hundreds of millions Series B financing round. This round of financing was co-invested by Galaxy Innovation Capital, Haier Capital and Hunan Medicine Development Private Equity Fund. This is another funding round for WillingMed in a short period of time after the Series A funding, indicating the high recognition of WillingMed by the capital market.

The funds raised in this round will be mainly used for medical device product registration and certification, new product development, "pathogenic microbial skynet laboratory" construction and other strategic layout to accelerate the implementation.

WillingMed Technology(Beijing) Co., Ltd. was established in 2019, as a national high-tech enterprise based on molecular biology technology platform, focusing on clinical infection precision diagnosis, the core technology backbone of Microrock Medical comes from Tsinghua University, Peking University, Chinese Academy of Sciences and other well-known research institutions at home and abroad, deeply cultivated in the field of pathogen detection for nearly 20 years, based on high-throughput sequencing (NGS), microfluidic chip, transcriptome sequencing, we have independently developed and successfully approved a number of automated testing instruments, software, testing reagents and other IVD products, and have obtained intellectual property rights for more than 40 core technologies. 

It has served more than 1,500 clinical hospitals and has been well received by clinical experts. It has also established strategic and project partnerships with many famous institutions such as the Institute of Microbiology of the Chinese Academy of Sciences, Peking Union Medical College Hospital, Peking University People's Hospital, China-Japan Friendship Hospital and Guangzhou Institute of Respiratory Health, and has achieved a series of academic results, which will lead a new era of precision diagnosis of infections. At present, we have established the "China Pathogenic Microorganism Skynet Laboratory" project with Runda Medical (A-share code: 603108), which will help China to rapidly improve its biosafety management capability.